Hepion Pharmaceuticals, Inc. (HEPA)

NASDAQ: HEPA · IEX Real-Time Price · USD
0.682
0.00 (0.00%)
At close: Mar 29, 2023, 12:00 AM
0.711
+0.030 (4.36%)
Pre-market: Mar 30, 2023, 9:07 AM EDT
Market Cap 52.60M
Revenue (ttm) n/a
Net Income (ttm) -45.12M
Shares Out 76.23M
EPS (ttm) -0.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,504
Open 0.700
Previous Close 0.682
Day's Range 0.671 - 0.700
52-Week Range 0.260 - 1.330
Beta 1.64
Analysts Buy
Price Target 3.57 (+423.84%)
Earnings Date Apr 14, 2023

About HEPA

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor bur... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D.
Employees 20
Stock Exchange NASDAQ
Ticker Symbol HEPA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for HEPA stock is "Buy." The 12-month stock price forecast is $3.57, which is an increase of 423.84% from the latest price.

Price Target
$3.57
(423.84% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Hepion Pharmaceuticals Expands SAB with Appointments of Four Liver Disease KOLs

EDISON, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic dru...

48 minutes ago - GlobeNewsWire

Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug Development

EDISON, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic dru...

1 week ago - GlobeNewsWire

Hepion Pharmaceuticals to Deliver Updates on Ongoing Phase 2 NASH Clinical Program with Rencofilstat at 6th Global NASH Congress

EDISON, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic dru...

3 weeks ago - GlobeNewsWire

EPO Decision to Grant European Patent for Rencofilstat Further Strengthens Hepion's Patent Portfolio

– Patent Covers 38 European Countries –

3 weeks ago - GlobeNewsWire

Hepion Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell on February 10, 2023

EDISON, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug...

1 month ago - GlobeNewsWire

Anti-Cancer Potential of Rencofilstat Expanded with Results from Preclinical Multiple Myeloma Studies

- Synergistic activity demonstrated with rencofilstat in combination with first line multiple myeloma drug, bortezomib -

2 months ago - GlobeNewsWire

Presentation of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors

EDISON, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug...

2 months ago - GlobeNewsWire

Hepion Pharmaceuticals to Present Phase 2a Rencofilstat Multiomics Data at NASH-TAG 2023

EDISON, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug...

2 months ago - GlobeNewsWire

Hepion Pharmaceuticals, Inc. Granted 180-day Extension by Nasdaq to Meet the Minimum Bid Price Requirements

EDISON, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (Nasdaq:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug...

4 months ago - GlobeNewsWire

Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 ‘ALTITUDE-NASH' Liver Function Trial

– Hepion Enrolls 60 F3 NASH Subjects in only 12 weeks, facilitated by AGILE 3+ non-invasive test –

4 months ago - GlobeNewsWire

Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock

EDISON, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug...

5 months ago - GlobeNewsWire

Hepion Pharmaceuticals Announces Publication of Phase 2a ‘AMBITION' Clinical Trial Results

- Study met safety, tolerability, and pharmacokinetics primary endpoints -

5 months ago - GlobeNewsWire

Hepion Pharmaceuticals Announces Publication of Food Effect Study with Rencofilstat

EDISON, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug...

5 months ago - GlobeNewsWire

Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology & HemeOnc Conference

EDISON, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic dru...

6 months ago - GlobeNewsWire

Upcoming Presentation at Joint Meeting of ISBRA and ESBRA to Highlight Potential of Hepion Pharmaceutical's Rencofilstat to Treat Alcohol-Related Liver Disease

EDISON, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic dru...

7 months ago - GlobeNewsWire

Hepion Pharmaceuticals Announces Further Adjournment of Annual Meeting of Stockholders

EDISON, N.J., July 22, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic ...

8 months ago - GlobeNewsWire

Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati

EDISON, N.J., June 28, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic ...

9 months ago - GlobeNewsWire

Hepion Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders

EDISON, N.J., June 24, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic ...

9 months ago - GlobeNewsWire

Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular Carcinoma

EDISON, N.J., June 20, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic ...

10 months ago - GlobeNewsWire

Hepion Pharmaceuticals to Present Five Posters at EASL International Liver Congress™ 2022

- Hepion Represented as Authors in Preclinical and Clinical Posters Related to Rencofilstat and Cyclophilins –

10 months ago - GlobeNewsWire

Hepion Pharmaceuticals Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting

EDISON, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug ...

10 months ago - GlobeNewsWire

CORRECTING and REPLACING - Hepion Pharmaceuticals, Inc.

EDISON, N.J., May 27, 2022 (GLOBE NEWSWIRE) -- In the press release issued earlier today by Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), we've been informed by the company that in both the headline and...

10 months ago - GlobeNewsWire

Hepion Pharmaceuticals Highlights Upcoming Phase 2 Clinical Trials of Recofilstat at 5th Global NASH Congress

EDISON, N.J., May 27, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug ...

10 months ago - GlobeNewsWire

Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial

- HepQuant Evaluation Offers Sensitive Measurement of Hepatic Function and Correlation with Clinical Outcomes -

11 months ago - GlobeNewsWire

Is Hepion Pharmaceuticals, Inc. (HEPA) Stock Outpacing Its Medical Peers This Year?

Here is how Hepion Pharmaceuticals, Inc. (HEPA) and ICU Medical (ICUI) have performed compared to their sector so far this year.

1 year ago - Zacks Investment Research